Turn $1,000 into $1.57 Million - with "Holy Grail of Medicine"

The following is a third party sponsored message. It should not be considered a recommendation or endorsement by Investing Daily or any of its affiliates. Dear Investor, On September 10, 2018, a tiny Cambridge biotech firm won a patent on a new kind of genetic software that can "Cut & Paste" any disease from your body. This revolutionary new kind of treatment will not just change medicine - It has the potential to eliminate genetic disease from our species. If that sounds like science fiction, consider this - The Nobel Prize Committee is calling it "The Holy Grail of Medicine" The Wall Street Journal reports the company is "transforming medicine." 60 Minutes reports the company is "revolutionizing the search for new drugs." And the biggest drug companies have rushed to invest over a $1 billion in the past year alone - Juno Pharma invested $700 million. Glaxo SmithKline invested $350 million. Johnson and Johnson invested $292 million. That's on top of the $120 million Bill Gates and Google Ventures already invested into this. The list goes on and on... Never before has so much money invested in a new treatment so quickly. And because of that, it's going to create more millionaires than any other single breakthrough in history. More than the internet, more than computers, more than cars. Investor's Business Daily estimates the market is worth at least $75 billion market. But right now, its stock price is just a tiny fraction of that size. Our research proves that anyone who gets in today could turn every $1,000 into $1.57 million (or more)! That's if the company doesn't get taken over for fast 300% gains first. CLICK HERE to see how you can profit from this rare opportunity >>> Sincerely, Dylan Jovine Behind the Markets "The Buck Stops Here" The preceding message is an advertisement from a carefully selected third party sponsor. The views expressed are solely those of the advertiser and are not necessarily those of Investing Daily. While this message has been sent to you at indra21poetra@gmail.com as part of your relationship with Investing Daily, it does not constitute endorsement of the advertiser, products or services by Investing Daily. We respect your privacy and you can rest assured that your personal information is never shared with this or any other outside party. For more information on how we protect your personal information, please read our Privacy Policy on InvestingDaily.com, or click the "Preferences" link below to update your subscription status. You are receiving this email at indra21poetra@gmail.com as part of your subscription to Investing Daily's Marketplace Review, published by Investing Daily. To ensure delivery directly to your inbox, please add postoffice@investingdaily.com to your address book today. Preferences | About Us | Contact Us | Privacy Policy Copyright 2019 Investing Daily. All rights reserved. Investing Daily, a division of Capitol Information Group, Inc. 7600A Leesburg Pike West Building, Suite 300 Falls Church, VA 22043-2004 U.S.A.